The firm said in an SEC document that it may from time to time offer common stock, preferred stock, warrants, and overallotment purchase rights and units.
The firm’s biopharma revenues increased 11 percent, while clinical service revenues grew 20 percent, and discovery service revenue increased 12 percent.
Cancer Genetics will help analyze biomarkers to identify response patient populations, as well as reflect the mechanism of action of Effector's eFT508.
Its CEO said the firm has a clear path to achieving profitability, and that a big-data and artificial intelligence initiative will further expand its margins.
The companies will develop biomarkers of response to Lantern's lead therapy candidates, including a potential liquid biopsy assay for its NSCLC drug Tavocept.
There was a lot of growth in the precision medicine field in the past year, and some experts believe the FDA's decision to hold off on regulating LDTs could spur more innovation.
A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.
